Tenax Therapeutics (NASDAQ:TENX) Issues Quarterly Earnings Results

Tenax Therapeutics (NASDAQ:TENX) announced its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.93, Zacks reports.

Tenax Therapeutics Stock Performance

Shares of NASDAQ:TENX traded down $0.05 during trading on Wednesday, hitting $6.99. The company’s stock had a trading volume of 17,953 shares, compared to its average volume of 43,563. The business has a 50 day moving average price of $6.93 and a two-hundred day moving average price of $6.27. Tenax Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $8.24. The company has a market capitalization of $31.90 million, a PE ratio of -7.60 and a beta of 1.52.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TENX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Tuesday. Wall Street Zen raised Tenax Therapeutics to a “sell” rating in a research report on Saturday, October 25th. Piper Sandler started coverage on shares of Tenax Therapeutics in a report on Monday, September 8th. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, Guggenheim lowered their price objective on Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tenax Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.